Peringatan Keamanan

Overdosage of succinylcholine is likely to extend the neuromuscular blockade beyond the time needed for surgery. Symptoms are likely to be consistent with its therapeutic effects, although more pronounced, and may therefore include skeletal muscle weakness, decreased respiratory reserve, low tidal volume, or apnea. Treatment of succinylcholine overdose involves airway and respiratory support until recovery of normal respiration is assured.L9004

Depending on the extent of the overdose, the characteristic depolarizing (i.e. Phase I) neuromuscular blockade may switch to resemble more closely a non-depolarizing (i.e. Phase II) neuromuscular blockade.L9004 This occurs primarily when succinylcholine is given over a prolonged period of time or with particularly large doses, and may result in significant respiratory muscle paralysis or weakness.

Succinylcholine

DB00202

small molecule approved

Deskripsi

Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter acetylcholine (ACh) linked by their acetyl groups.A19054 It has been widely used for over 50 years,A299 most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation.L9004

Struktur Molekul 2D

Berat 290.399
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean half-life of elimination following intravenous administration is 47 seconds.[A233225]
Volume Distribusi At intravenous doses of 1 mg/kg and 2 mg/kg in 14 patients, the mean apparent volumes of distribution were 16.4 ± 14.7 and 5.6 ± 6.8 mL/kg, respectively.[A233235]
Klirens (Clearance) The mean _in vivo_ plasma clearance of succinylcholine following an intravenous dose of 1 mg/kg in 18 patients was approximately 4.17 ± 2.37 L/min.[A233220]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Succinylcholine is rapidly metabolized by plasma cholinesterase in the bloodstream to succinylmonocholine, which is then further hydrolyzed (albeit more slowly) to succinic acid and choline.L32828

Rute Eliminasi

Approximately 10% of an administered dose is excreted unchanged in the urine.L32828

Interaksi Obat

1172 Data
Buprenorphine Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Hydrocodone Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Magnesium sulfate The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Succinylcholine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Mirtazapine Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Orphenadrine Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Pramipexole Succinylcholine may increase the sedative activities of Pramipexole.
Ropinirole Succinylcholine may increase the sedative activities of Ropinirole.
Rotigotine Succinylcholine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Succinylcholine.
Sodium oxybate The risk or severity of CNS depression can be increased when Succinylcholine is combined with Sodium oxybate.
Suvorexant Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
Thalidomide Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Morphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Morphine.
Codeine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Codeine.
Hydromorphone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Hydromorphone.
Meperidine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meperidine.
Oxycodone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxycodone.
Butorphanol The risk or severity of bradycardia can be increased when Succinylcholine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Pentazocine.
Naltrexone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naltrexone.
Sufentanil The risk or severity of bradycardia can be increased when Succinylcholine is combined with Sufentanil.
Alfentanil The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alfentanil.
Fentanyl The risk or severity of bradycardia can be increased when Succinylcholine is combined with Fentanyl.
Nalbuphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nalbuphine.
Levorphanol The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levorphanol.
Remifentanil The risk or severity of bradycardia can be increased when Succinylcholine is combined with Remifentanil.
Diphenoxylate The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diphenoxylate.
Oxymorphone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxymorphone.
Dezocine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dezocine.
Levacetylmethadol The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of bradycardia can be increased when Succinylcholine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydroetorphine.
Diamorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diamorphine.
Bezitramide The risk or severity of bradycardia can be increased when Succinylcholine is combined with Bezitramide.
Ethylmorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ethylmorphine.
Etorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Etorphine.
Dextromoramide The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextromoramide.
Desomorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Desomorphine.
Carfentanil The risk or severity of bradycardia can be increased when Succinylcholine is combined with Carfentanil.
Dihydrocodeine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydromorphine.
Ketobemidone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ketobemidone.
DPDPE The risk or severity of bradycardia can be increased when Succinylcholine is combined with DPDPE.
Lofentanil The risk or severity of bradycardia can be increased when Succinylcholine is combined with Lofentanil.
Eluxadoline The risk or severity of bradycardia can be increased when Succinylcholine is combined with Eluxadoline.
Opium The risk or severity of bradycardia can be increased when Succinylcholine is combined with Opium.
Normethadone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Normethadone.
Piritramide The risk or severity of bradycardia can be increased when Succinylcholine is combined with Piritramide.
Alphaprodine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alphaprodine.
Nicomorphine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nicomorphine.
Meptazinol The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meptazinol.
Phenoperidine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Phenoperidine.
Phenazocine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Phenazocine.
Tilidine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of bradycardia can be increased when Succinylcholine is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of bradycardia can be increased when Succinylcholine is combined with Benzhydrocodone.
Naloxegol The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naloxegol.
Bambuterol The therapeutic efficacy of Succinylcholine can be increased when used in combination with Bambuterol.
Capreomycin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Capreomycin.
Botulinum toxin type B The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type B.
Botulinum toxin type A The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type A.
Cyclosporine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.
Doxycycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Doxycycline.
Lymecycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lymecycline.
Piperacillin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Piperacillin.
Framycetin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Framycetin.
Clomocycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Clomocycline.
Quinine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinine.
Vancomycin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Vancomycin.
Tigecycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tigecycline.
Oxytetracycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Oxytetracycline.
Chloroquine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Chloroquine.
Demeclocycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Demeclocycline.
Mecamylamine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Mecamylamine.
Tobramycin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tobramycin.
Tetracycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tetracycline.
Gentamicin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Gentamicin.
Etacrynic acid The therapeutic efficacy of Succinylcholine can be increased when used in combination with Etacrynic acid.
Quinidine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinidine.
Metacycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Metacycline.
Netilmicin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Netilmicin.
Neomycin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Neomycin.
Streptomycin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Streptomycin.
Colistimethate The therapeutic efficacy of Succinylcholine can be increased when used in combination with Colistimethate.
Kanamycin The therapeutic efficacy of Succinylcholine can be increased when used in combination with Kanamycin.
Rolitetracycline The therapeutic efficacy of Succinylcholine can be increased when used in combination with Rolitetracycline.

Target Protein

Neuronal Acetylcholine (nACh) Receptor Subunits CHRNA10
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M3 CHRM3

Referensi & Sumber

Synthesis reference: Walter Raml, Gunther Eichberger, "Process for the preparation of succinylcholine halides." U.S. Patent US5206420, issued April 27, 1993.
Artikel (PubMed)
  • PMID: 16571968
    Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33.
  • PMID: 26398623
    Alvarellos ML, McDonagh EM, Patel S, McLeod HL, Altman RB, Klein TE: PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2015 Dec;25(12):622-30. doi: 10.1097/FPC.0000000000000170.
  • PMID: 14564614
    Kato M, Shiratori T, Yamamuro M, Haga S, Hoshi K, Matsukawa S, Jalal IM, Hashimoto Y: Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. J Anesth. 1999 Oct 30;13(4):189-92. doi: 10.1007/s005400050055.
  • PMID: 9209610
    Torda TA, Graham GG, Warwick NR, Donohue P: Pharmacokinetics and pharmacodynamics of suxamethonium. Anaesth Intensive Care. 1997 Jun;25(3):272-8. doi: 10.1177/0310057X9702500312.
  • PMID: 16571955
    Martyn J, Durieux ME: Succinylcholine: new insights into mechanisms of action of an old drug. Anesthesiology. 2006 Apr;104(4):633-4.
  • PMID: 8122251
    Hoshi K, Hashimoto Y, Matsukawa S: Pharmacokinetics of succinylcholine in man. Tohoku J Exp Med. 1993 Aug;170(4):245-50. doi: 10.1620/tjem.170.245.
  • PMID: 29763160
    Hager HH, Burns B: Succinylcholine Chloride .

Contoh Produk & Brand

Produk: 75 • International brands: 2
Produk
  • Anectine
    Injection, solution • 20 mg/1mL • Intramuscular; Intravenous; Parenteral • US • Approved
  • Anectine
    Injection, solution • 20 mg/1mL • Intramuscular; Intravenous; Parenteral • US • Approved
  • Anectine
    Injection, solution • 20 mg/1mL • Intramuscular; Intravenous; Parenteral • US • Approved
  • Anectine
    Injection, solution • 20 mg/1mL • Intramuscular; Intravenous; Parenteral • US • Approved
  • Anectine
    Injection, solution • 20 mg/1mL • Intramuscular; Intravenous; Parenteral • US • Approved
  • Anectine Civ
    Injection, solution • 20 mg/1mL • Intramuscular; Intravenous; Parenteral • US • Approved
  • Anectine Flopack 500mg
    Powder, for solution • 500 mg / pck • Intravenous • Canada • Approved
  • Anectine Inj 20mg/ml
    Liquid • 20 mg / mL • Intravenous • Canada • Approved
Menampilkan 8 dari 75 produk.
International Brands
  • Scoline
  • Sucostrin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul